78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (D GC) in patients (pts) with advanced biliary tract cancer (BTC) (vol 33, pg s1462, 2022)
Authors
Oh, D.He, A. R.
Qin, S.
Chen, L.
Okusaka, T.
Vogel, A.
Kim, J. W.
Suksombooncharoen, T.
Lee, M. A.
Kitano, M.
Burris, H. A.
Bouattour, M.
Tanasa, S.
Zaucha, R. E.
Avallone, A.
Cundom, J. E.
Rokutanda, N.
Zotkiewicz, M.
Cohen, G.
Valle, Juan W
Affiliation
Division Of Medical Oncology, Department Of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, 110-744 - Seoul/KRIssue Date
2023
Metadata
Show full item recordCitation
Oh D, He AR, Qin S, Chen L, Okusaka T, Vogel A, et al. 78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (D GC) in patients (pts) with advanced biliary tract cancer (BTC) (vol 33, pg s1462, 2022). Annals of Oncology. 2023 Jul;34(7):633-. PubMed PMID: WOS:001033922200001.Journal
Annals of OncologyDOI
10.1016/annonc/annonc1123Additional Links
https://dx.doi.org/10.1016/annonc/annonc1123Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/annonc/annonc1123